Botanical species · safety record

Crotalaria sessiliflora

The EFSA Compendium of Botanicals holds 7 constituent measurements and 1 adverse-effect record for Crotalaria sessiliflora. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Crotalaria sessiliflora L.

7Constituent measurements

1Safety records

5Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Isoflavones	Aerial part of plants	—	—	—	Resolve DOI
Isoflavones	Aerial part of plants	Solvent extraction	—	HPLC with standard detection methods	Resolve DOI
Hydroquinone	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Integerrimine	Seed	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Monocrotaline	Seed	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Pyrrolizidine alkaloids	Unspecified	—	—	—	No resolvable identifier
Trichodesmine	Seed	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Endocrine	—	Aerial part of plants	Solvent extraction	—	In vitro	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Yoo, HS., Lee, JS., Kim, CY., Kim, J. Flavonoids of Crotalaria sessiliflora. ARCHIVES OF PHARMACAL RESEARCH, 2004, vol. 27, no. 5, p. 544-546. DOI
Lin, Ge., Li, Na., Li, Mi., Chan, Wood-Yee., Fu, Peter P., Xu, Hong-Xi. Potential biomarker for the assessment of hepatotoxicity induced by metabolic activation of pyrrolizidine alkaloids. DRUG METABOLISM REVIEWS, 2010, vol. 42, p. 207-207.
Roeder, E., Liang, X. T., Kabus, K. J. Pyrrolizidine alkaloids from the seeds of Crotalaria sessiliflora. Planta Medica, 1992.
Mun'im, A., Isoda, H., Seki, M., Negishi, O., Ozawa, T. Estrogenic and acetylcholinesterase-enhancement activity of a new isoflavone, 7,2 ',4 '-trihydroxyisoflavone-4 '-O-beta-D-glucopyranoside from Crotalaria sessililflora. CYTOTECHNOLOGY, 2003, vol. 43, no. 1-3, p. 127-134. DOI
Mun'im, A., Negishi, O., Ozawa, T. Antioxidative compounds from Crotalaria sessiliflora. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2003, vol. 67, no. 2, p. 410-414.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature